Johnson & Johnson stock hits 52-week low at $142.7

Published 08-01-2025, 08:08 pm

In a challenging market environment, Johnson & Johnson's stock has touched a 52-week low, dipping to $142.7. This downturn reflects a broader trend for the healthcare giant, which has seen its shares decline by 6.61% over the past year. Investors are closely monitoring the company's performance, particularly with earnings due in 14 days. Despite market volatility, JNJ maintains a GOOD financial health score and offers a 3.39% dividend yield, demonstrating its continued strength in the healthcare sector. For deeper insights into JNJ's valuation and growth prospects, access the comprehensive Pro Research Report available on InvestingPro. The 52-week low also serves as a critical benchmark for the company's valuation, possibly affecting strategic decisions and investor confidence. InvestingPro data shows the stock generally trades with low price volatility, with additional ProTips available to subscribers regarding the company's financial stability and market position.

In other recent news, Johnson & Johnson has made significant strides in its Alzheimer's and lung cancer treatments. The company has received FDA Fast Track designations for two investigational Alzheimer's therapies, posdinemab and JNJ-2056, aimed at slowing cognitive decline and preventing disease progression. Concurrently, Johnson & Johnson reported positive results from its Phase 3 MARIPOSA study, showing a survival benefit in lung cancer treatment with the combination therapy of RYBREVANT® and LAZCLUZE™.

In addition to these developments, Johnson & Johnson is dealing with over 62,000 lawsuits alleging asbestos contamination in its talc products. In response, the FDA has proposed standardized testing for asbestos in talc cosmetics. Amid these developments, RBC Capital maintains its Outperform rating on Johnson & Johnson, citing promising results from its drugs DARZALEX, CARVYKTI, and TECVAYLI.

The company also reported strong Q3 results with operational sales growth of 6.3%, reaching $22.5 billion. These recent developments are part of Johnson & Johnson's ongoing efforts to bring innovative treatments to market and address unmet medical needs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.